Biotheranostics, a subsidiary of Hologic, is a leading provider of proprietary genomic assays for personalized disease management in oncology, offering tests such as Breast Cancer Index and CancerTYPE ID. Their genomic tests are recognized by ASCO and NCCN Clinical Practice Guidelines, providing valuable insights for predicting the benefit of extended endocrine therapy in HR-positive, early-stage breast cancer and identifying tumor type and subtype for metastatic cancer patients with unknown or unclear diagnoses.
With a commitment to precision medicine, Biotheranostics utilizes cutting-edge technology to support clinicians in making informed treatment decisions, ultimately improving patient outcomes. Their assays are backed by extensive validation and are trusted by healthcare professionals worldwide, making Biotheranostics a key player in the field of genomic testing for oncology.
Generated from the website